-+ 0.00%
-+ 0.00%
-+ 0.00%
Bausch + Lomb's BL1332 misses primary endpoint in Phase 2 ocular pain trial
Share
Listen to the news
Bausch + Lomb's BL1332 misses primary endpoint in Phase 2 ocular pain trial
  • Bausch + Lomb reported BL1332 missed its primary pain-relief endpoint in a Phase 2 trial following photorefractive keratectomy surgery.
  • Both doses showed numerically greater pain relief than vehicle; exploratory findings suggested faster corneal healing.
  • BL1332 was well tolerated, with no treatment-related adverse events or new safety signals.
  • The findings will inform FDA discussions on future development, including potential Phase 3 planning.
  • Management will present the results today at 5 p.m. ET.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611191615BIZWIRE_USPR_____20261118_BW969505) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending